A Study on the Use of Tanakan® for Recovery of Neurological Impairment Following Ischaemic Stroke

• Status: Completed
• Trial end date: 2009-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effectiveness of Tanakan® 240mg in association with Acetylsalicylic acid (325mg/day) in the recovery of neurological impairment following ischemic stroke.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Ipsen
• Treatments: Aspirin

Criteria

Inclusion Criteria:

• Patient having had a single infarct in the carotid artery territory 3 to 8 days before inclusion

• Patient with a moderately severe or severe disability (Modified Rankin Score 4 or 5)

• Patient having a Quick's Test (for INR) and APPT (activated partial prothrombin time) test in the normal values of the laboratory

Exclusion Criteria:

• Patients having had an ischemic stroke (CT confirmed) less than 3 days and more than 8 days prior

• Patient with known pre-existent cerebral infarction

• Infarct damaged area bigger than 1/3 hemisphere

• Patient having a score below the cut-off point at Frenchay Aphasia Short Test